Article Index

HOPA Oncology Pharmacy Practice Literature Award

This award recognizes an author who has written an article, other than scientific research, that contributes significantly to the betterment of the hematology/oncology pharmacy profession and describes innovations in community, hospital, or healthcare system hematology/oncology pharmacy practices that are applicable beyond the practice site where they were developed and/or evaluated.

2022 Shannon Hough, PharmD, BCOP

Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage JB. Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncol Pract. 2021 Feb 3:OP2000639. doi: 10.1200/OP.20.00639

2021 Grant Lee, PharmD

Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NTN. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Sep 17;1078155220957738. PubMed PMID: 32938297.

2020 Jacqueline L. Olin, M.S., PharmD, BCPS

Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother 2019 Aug;53(8):812-832. doi: 10.1177/1060028019833038. Epub 2019 Feb 15.

2019 Julianne Orr, PharmD BCOP

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, Deremer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018;24(10):2065–71.

2017 Karen Sweiss, PharmD

Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016; e-pub ahead of print 16 May 2016; doi:10.1038/bmt.2016.136.

2016    Ginah Nightingale, PharmD BCOP

Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453-1459.

2015    Joseph S. Bubalo, PharmD BCOP BCPS

Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi:10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23.

2014    Ali McBride, PharmD MS BCPS BCOP

McBride A, Lathon S, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. Pharmacotherapy. 2013;33(3):295-303.

2013    Kamakshi V. Rao, PharmD BCOP CPP

Strother RM, Rao KV, Gregory KM, Jakait B, Busakhala N, Schellhase E, Pastakia S, Krzyzanowski M, Loehrer PJ. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012. Jan 16

2012    Kristine R. Crews, PharmD, BCPS

Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011

2010    Brian Crandell, PharmD, BCOP

O'Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632-9.